Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 25621 | 20.05 |
09:34 ET | 19221 | 19.98 |
09:36 ET | 5205 | 20.085 |
09:38 ET | 6763 | 20.1895 |
09:39 ET | 26559 | 19.955 |
09:41 ET | 2343 | 20.005 |
09:43 ET | 3355 | 20 |
09:45 ET | 9135 | 19.954 |
09:48 ET | 773 | 19.98 |
09:50 ET | 6646 | 19.8688 |
09:52 ET | 22681 | 19.84 |
09:54 ET | 3723 | 19.9 |
09:56 ET | 12200 | 19.89 |
09:57 ET | 4113 | 19.87 |
09:59 ET | 11001 | 19.75 |
10:01 ET | 19655 | 19.68 |
10:03 ET | 2104 | 19.75 |
10:06 ET | 4245 | 19.75 |
10:08 ET | 5500 | 19.78 |
10:10 ET | 6434 | 19.8037 |
10:12 ET | 5231 | 19.785 |
10:14 ET | 3520 | 19.78 |
10:15 ET | 2662 | 19.765 |
10:17 ET | 5670 | 19.6997 |
10:19 ET | 5954 | 19.645 |
10:21 ET | 29535 | 19.66 |
10:24 ET | 4739 | 19.65 |
10:26 ET | 6411 | 19.6221 |
10:28 ET | 13433 | 19.605 |
10:30 ET | 1500 | 19.595 |
10:32 ET | 37904 | 19.61 |
10:33 ET | 12603 | 19.64 |
10:35 ET | 10199 | 19.645 |
10:37 ET | 5808 | 19.645 |
10:39 ET | 6002 | 19.66 |
10:42 ET | 4389 | 19.66 |
10:44 ET | 11106 | 19.66 |
10:46 ET | 8913 | 19.67 |
10:48 ET | 6523 | 19.7 |
10:50 ET | 6952 | 19.71 |
10:51 ET | 5471 | 19.74 |
10:53 ET | 3655 | 19.83 |
10:55 ET | 5051 | 19.87 |
10:57 ET | 29924 | 19.86 |
11:00 ET | 5374 | 19.82 |
11:02 ET | 2841 | 19.86 |
11:04 ET | 4366 | 19.9 |
11:06 ET | 4050 | 19.895 |
11:08 ET | 40123 | 19.82 |
11:09 ET | 6372 | 19.86 |
11:11 ET | 15276 | 19.825 |
11:13 ET | 8196 | 19.8126 |
11:15 ET | 2300 | 19.83 |
11:18 ET | 14752 | 19.82 |
11:20 ET | 4147 | 19.85 |
11:22 ET | 3818 | 19.82 |
11:24 ET | 2854 | 19.82 |
11:26 ET | 3117 | 19.83 |
11:27 ET | 1840 | 19.82 |
11:29 ET | 3364 | 19.785 |
11:31 ET | 6116 | 19.8 |
11:33 ET | 4404 | 19.805 |
11:36 ET | 2970 | 19.78 |
11:38 ET | 20221 | 19.735 |
11:40 ET | 6099 | 19.68 |
11:42 ET | 1662 | 19.6602 |
11:44 ET | 2221 | 19.65 |
11:45 ET | 18621 | 19.68 |
11:47 ET | 2589 | 19.74 |
11:49 ET | 7217 | 19.7399 |
11:51 ET | 9298 | 19.73 |
11:54 ET | 8060 | 19.73 |
11:56 ET | 6937 | 19.72 |
11:58 ET | 9141 | 19.7 |
12:00 ET | 2481 | 19.7725 |
12:02 ET | 2898 | 19.75 |
12:03 ET | 3961 | 19.675 |
12:05 ET | 23055 | 19.7 |
12:07 ET | 5014 | 19.65 |
12:09 ET | 4882 | 19.6602 |
12:12 ET | 19418 | 19.62 |
12:14 ET | 1800 | 19.615 |
12:16 ET | 4232 | 19.59 |
12:18 ET | 30713 | 19.54 |
12:20 ET | 36023 | 19.53 |
12:21 ET | 11839 | 19.53 |
12:23 ET | 31503 | 19.5499 |
12:25 ET | 2460 | 19.53 |
12:27 ET | 9618 | 19.555 |
12:30 ET | 5808 | 19.61 |
12:32 ET | 5273 | 19.615 |
12:34 ET | 12976 | 19.65 |
12:36 ET | 1322 | 19.62 |
12:38 ET | 3632 | 19.63 |
12:39 ET | 1395 | 19.625 |
12:41 ET | 4719 | 19.6 |
12:43 ET | 27746 | 19.72 |
12:45 ET | 1800 | 19.705 |
12:48 ET | 5025 | 19.7 |
12:50 ET | 1300 | 19.68 |
12:52 ET | 4895 | 19.73 |
12:54 ET | 10381 | 19.7 |
12:56 ET | 9210 | 19.677 |
12:57 ET | 2950 | 19.7 |
12:59 ET | 5354 | 19.7099 |
01:01 ET | 1487 | 19.71 |
01:03 ET | 3984 | 19.72 |
01:06 ET | 11513 | 19.74 |
01:08 ET | 9974 | 19.75 |
01:10 ET | 6089 | 19.73 |
01:12 ET | 4615 | 19.785 |
01:14 ET | 1883 | 19.77 |
01:15 ET | 4576 | 19.78 |
01:17 ET | 2681 | 19.815 |
01:19 ET | 4485 | 19.79 |
01:21 ET | 1284 | 19.77 |
01:24 ET | 1200 | 19.76 |
01:26 ET | 7825 | 19.725 |
01:28 ET | 1200 | 19.735 |
01:30 ET | 4822 | 19.73 |
01:32 ET | 2902 | 19.8 |
01:33 ET | 3600 | 19.79 |
01:35 ET | 900 | 19.835 |
01:37 ET | 3661 | 19.86 |
01:39 ET | 14225 | 19.91 |
01:42 ET | 7374 | 19.86 |
01:44 ET | 3332 | 19.83 |
01:46 ET | 1750 | 19.845 |
01:48 ET | 2425 | 19.86 |
01:50 ET | 4518 | 19.7701 |
01:51 ET | 904 | 19.78 |
01:53 ET | 8204 | 19.81 |
01:55 ET | 3450 | 19.81 |
01:57 ET | 1900 | 19.78 |
02:00 ET | 3712 | 19.77 |
02:02 ET | 800 | 19.76 |
02:04 ET | 3480 | 19.785 |
02:06 ET | 7532 | 19.795 |
02:08 ET | 2781 | 19.78 |
02:09 ET | 571 | 19.79 |
02:11 ET | 2600 | 19.8199 |
02:13 ET | 2731 | 19.77 |
02:15 ET | 6377 | 19.78 |
02:18 ET | 1890 | 19.7868 |
02:20 ET | 3508 | 19.75 |
02:22 ET | 2163 | 19.79 |
02:24 ET | 1190 | 19.8 |
02:26 ET | 1200 | 19.83 |
02:27 ET | 5908 | 19.8 |
02:29 ET | 3120 | 19.77 |
02:31 ET | 3612 | 19.77 |
02:33 ET | 1800 | 19.795 |
02:36 ET | 5239 | 19.77 |
02:38 ET | 2238 | 19.82 |
02:40 ET | 500 | 19.82 |
02:42 ET | 3275 | 19.82 |
02:44 ET | 1962 | 19.81 |
02:45 ET | 7301 | 19.795 |
02:47 ET | 2907 | 19.81 |
02:49 ET | 7793 | 19.8533 |
02:51 ET | 9375 | 19.86 |
02:54 ET | 4048 | 19.87 |
02:56 ET | 3793 | 19.8732 |
02:58 ET | 4087 | 19.83 |
03:00 ET | 14126 | 19.835 |
03:02 ET | 3273 | 19.91 |
03:03 ET | 2925 | 19.9 |
03:05 ET | 4957 | 19.9 |
03:07 ET | 3008 | 19.835 |
03:09 ET | 4163 | 19.83 |
03:12 ET | 4540 | 19.86 |
03:14 ET | 1871 | 19.86 |
03:16 ET | 8009 | 19.84 |
03:18 ET | 2037 | 19.85 |
03:20 ET | 34234 | 19.8 |
03:21 ET | 10037 | 19.84 |
03:23 ET | 9177 | 19.84 |
03:25 ET | 4773 | 19.84 |
03:27 ET | 5506 | 19.9 |
03:30 ET | 5415 | 19.925 |
03:32 ET | 7970 | 19.92 |
03:34 ET | 6823 | 19.91 |
03:36 ET | 7671 | 19.92 |
03:38 ET | 1871 | 19.93 |
03:39 ET | 19972 | 19.895 |
03:41 ET | 5007 | 19.88 |
03:43 ET | 7232 | 19.93 |
03:45 ET | 14585 | 19.925 |
03:48 ET | 8577 | 19.89 |
03:50 ET | 10371 | 19.89 |
03:52 ET | 27108 | 19.87 |
03:54 ET | 15124 | 19.875 |
03:56 ET | 35431 | 19.87 |
03:57 ET | 35507 | 19.865 |
03:59 ET | 704512 | 19.92 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 3.1B | 90.3x | --- |
Twist Bioscience Corp | 2.6B | -11.5x | --- |
ADMA Biologics Inc | 3.7B | -782.4x | --- |
MorphoSys AG | 2.8B | -5.5x | --- |
Arrowhead Pharmaceuticals Inc | 2.9B | -5.0x | --- |
Vericel Corp | 2.2B | 2,411.4x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
---|---|
Revenue (TTM) | $289.3M |
Shares Outstanding | 154.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.18 |
EPS | $0.22 |
Book Value | $1.06 |
P/E Ratio | 90.3x |
Price/Sales (TTM) | 10.6 |
Price/Cash Flow (TTM) | 74.4x |
Operating Margin | 16.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.